(Total Views: 743)
Posted On: 07/24/2021 3:11:59 PM
Post# of 148870
Some CYDY events listed during various periods of certain management & board members
Director, Caracciolo
September 11, 2012 Nadar Pourhassan named CEO
https://www.cytodyn.com/newsroom/press-releas...-announces
Director, Caracciolo
CEO, Pourhassan
July 30, 2012 Cytodyn buys pro140, Nader is CEO at that time
https://www.cytodyn.com/newsroom/press-releas...-progenics
June 17, 2013 Tony Caracciolo is named Chairman of the Board
https://www.cytodyn.com/newsroom/press-releas...hairman-of
COB, Caracciolo
CEO, Pourhassan
January 30, 2017 Tony Caracciolo is named Executive Chairman, effectively replacing Nader. Nader is still CEO, but Tony is in charge of planning, business development, and operations.
https://www.cytodyn.com/newsroom/press-releas...ppointment
COB & Executive Chairman, Caracciolo
CEO, Pourhassan
April 11, 2017 Scott Kelly appointed as Director
https://www.cytodyn.com/newsroom/press-releas...s-board-of
COB & Executive Chairman, Caracciolo
Director, Kelly
CEO, Pourhassan
July 12, 2018 Cytodyn signs letter of intent to purchase Prostagene & intent to appoint Pestell as Chief Medical Officer. AND ALSO Anthony Caracciolo has resigned his operating position as Executive Chairman and will continue to serve as Chairman of the Board
https://www.cytodyn.com/newsroom/press-releas...h-expanded
COB, Caracciolo
CEO, Pourhassan
August 18, 2018 Cytodyn agrees to buy Prostagene, Pestell becomes interim Chief Medical Officer
https://www.cytodyn.com/newsroom/press-releas...prostagene
COB, Caracciolo
CEO, Pourhassan
CMO (interim), Pestell
September 5, 2018 plan to develop mTNBC as initial cancer indication
https://www.cytodyn.com/newsroom/press-releas...metastatic
October 9, 2018 strategy to get test results on Prostagene 4 months after acquisition completes
https://www.cytodyn.com/newsroom/press-releas...t-of-novel
November 5, 2018 mTNBC trial protocol filed
https://www.cytodyn.com/newsroom/press-releas...2-clinical
November 19, 2018 Prostagene acquisition finalized, Pestell appointed to the Board and becomes Chief Science Officer
https://www.cytodyn.com/newsroom/press-releas...d-names-dr
COB, Caracciolo
CEO, Pourhassan
CMO & Director, Pestell
November 26 2018 mTNBC trial initiates (but 1st patient starts about 8 months later on 08/06/19
https://www.cytodyn.com/newsroom/press-releas...e-negative
December 12, 2018 Tony Caracciolo is replaced by Scott Kelly as Chairman of the Board
https://www.cytodyn.com/newsroom/press-releas...-the-board
COB, Kelly
Director, Caracciolo
CEO, Pourhassan
CMO & Director, Pestell
January 7, 2019 Pestell named as Vice Chairman of its Board of Directors
https://www.cytodyn.com/newsroom/press-releas...-d-as-vice
COB, Kelly
Director, Caracciolo
CEO, Pourhassan
CMO & Vice Chairman of Board, Pestell
January 10, 2019 Tony Caracciolo resigned as a member of the Company’s board of directors
https://www.sec.gov/edgar/search/?r=el#d688532d8k.htm
COB, Kelly
CEO, Pourhassan
CMO & Vice Chairman of Board, Pestell
June 19, 2019 filed FDA pre-submission application for Prostagene test
https://www.cytodyn.com/newsroom/press-releas...ion-to-u-s
June 24, 2019 FDA face-to-face meeting about Prostagene test
https://www.cytodyn.com/newsroom/press-releas...s-cytodyns
July 25, 2019 terminated the employment of Dr. Richard G. Pestell, the Company’s Chief Medical Officer, for cause pursuant to the terms of his employment agreement with the Company and effective immediately. Pursuant to the terms of his employment agreement, upon such termination, Dr. Pestell resigned from his position as a director of the Company. Dr. Pestell was not a member of any board committees.
https://www.sec.gov/Archives/edgar/data/00011...262d8k.htm
COB, Kelly
CEO, Pourhassan
July 26, 2019 IncellDX agreement executed
https://www.cytodyn.com/newsroom/press-releas...-agreement
COB, Kelly
CEO, Pourhassan
IncellDX agreement
August 6, 2019 first mTNBC patient treated
https://www.cytodyn.com/newsroom/press-releas...metastatic
August 22, 2019 Pestell sues Cytodyn
https://www.sec.gov/Archives/edgar/data/00011...060d8k.htm
April 27, 2020 completed BLA for HIV combo filed
https://www.cytodyn.com/newsroom/press-releas...pplication
May 8, 2020 FDA requires more data for BLA to address comments mentioned in March 2020 meeting.
https://www.cytodyn.com/newsroom/press-releas...pplication
July,13 2020 FDA issues Refusal to File letter. The FDA has informed the Company its BLA does not contain certain information needed to complete a substantive review and therefore, the FDA will not file the BLA at this time.
https://www.cytodyn.com/newsroom/press-releas...rmation-to
IMO It may be interesting to see what the FDA did say about the receptor occupancy listed in the application from 2020.
Director, Caracciolo
September 11, 2012 Nadar Pourhassan named CEO
https://www.cytodyn.com/newsroom/press-releas...-announces
Director, Caracciolo
CEO, Pourhassan
July 30, 2012 Cytodyn buys pro140, Nader is CEO at that time
https://www.cytodyn.com/newsroom/press-releas...-progenics
June 17, 2013 Tony Caracciolo is named Chairman of the Board
https://www.cytodyn.com/newsroom/press-releas...hairman-of
COB, Caracciolo
CEO, Pourhassan
January 30, 2017 Tony Caracciolo is named Executive Chairman, effectively replacing Nader. Nader is still CEO, but Tony is in charge of planning, business development, and operations.
https://www.cytodyn.com/newsroom/press-releas...ppointment
COB & Executive Chairman, Caracciolo
CEO, Pourhassan
April 11, 2017 Scott Kelly appointed as Director
https://www.cytodyn.com/newsroom/press-releas...s-board-of
COB & Executive Chairman, Caracciolo
Director, Kelly
CEO, Pourhassan
July 12, 2018 Cytodyn signs letter of intent to purchase Prostagene & intent to appoint Pestell as Chief Medical Officer. AND ALSO Anthony Caracciolo has resigned his operating position as Executive Chairman and will continue to serve as Chairman of the Board
https://www.cytodyn.com/newsroom/press-releas...h-expanded
COB, Caracciolo
CEO, Pourhassan
August 18, 2018 Cytodyn agrees to buy Prostagene, Pestell becomes interim Chief Medical Officer
https://www.cytodyn.com/newsroom/press-releas...prostagene
COB, Caracciolo
CEO, Pourhassan
CMO (interim), Pestell
September 5, 2018 plan to develop mTNBC as initial cancer indication
https://www.cytodyn.com/newsroom/press-releas...metastatic
October 9, 2018 strategy to get test results on Prostagene 4 months after acquisition completes
https://www.cytodyn.com/newsroom/press-releas...t-of-novel
November 5, 2018 mTNBC trial protocol filed
https://www.cytodyn.com/newsroom/press-releas...2-clinical
November 19, 2018 Prostagene acquisition finalized, Pestell appointed to the Board and becomes Chief Science Officer
https://www.cytodyn.com/newsroom/press-releas...d-names-dr
COB, Caracciolo
CEO, Pourhassan
CMO & Director, Pestell
November 26 2018 mTNBC trial initiates (but 1st patient starts about 8 months later on 08/06/19
https://www.cytodyn.com/newsroom/press-releas...e-negative
December 12, 2018 Tony Caracciolo is replaced by Scott Kelly as Chairman of the Board
https://www.cytodyn.com/newsroom/press-releas...-the-board
COB, Kelly
Director, Caracciolo
CEO, Pourhassan
CMO & Director, Pestell
January 7, 2019 Pestell named as Vice Chairman of its Board of Directors
https://www.cytodyn.com/newsroom/press-releas...-d-as-vice
COB, Kelly
Director, Caracciolo
CEO, Pourhassan
CMO & Vice Chairman of Board, Pestell
January 10, 2019 Tony Caracciolo resigned as a member of the Company’s board of directors
https://www.sec.gov/edgar/search/?r=el#d688532d8k.htm
COB, Kelly
CEO, Pourhassan
CMO & Vice Chairman of Board, Pestell
June 19, 2019 filed FDA pre-submission application for Prostagene test
https://www.cytodyn.com/newsroom/press-releas...ion-to-u-s
June 24, 2019 FDA face-to-face meeting about Prostagene test
https://www.cytodyn.com/newsroom/press-releas...s-cytodyns
July 25, 2019 terminated the employment of Dr. Richard G. Pestell, the Company’s Chief Medical Officer, for cause pursuant to the terms of his employment agreement with the Company and effective immediately. Pursuant to the terms of his employment agreement, upon such termination, Dr. Pestell resigned from his position as a director of the Company. Dr. Pestell was not a member of any board committees.
https://www.sec.gov/Archives/edgar/data/00011...262d8k.htm
COB, Kelly
CEO, Pourhassan
July 26, 2019 IncellDX agreement executed
https://www.cytodyn.com/newsroom/press-releas...-agreement
COB, Kelly
CEO, Pourhassan
IncellDX agreement
August 6, 2019 first mTNBC patient treated
https://www.cytodyn.com/newsroom/press-releas...metastatic
August 22, 2019 Pestell sues Cytodyn
https://www.sec.gov/Archives/edgar/data/00011...060d8k.htm
April 27, 2020 completed BLA for HIV combo filed
https://www.cytodyn.com/newsroom/press-releas...pplication
May 8, 2020 FDA requires more data for BLA to address comments mentioned in March 2020 meeting.
https://www.cytodyn.com/newsroom/press-releas...pplication
July,13 2020 FDA issues Refusal to File letter. The FDA has informed the Company its BLA does not contain certain information needed to complete a substantive review and therefore, the FDA will not file the BLA at this time.
https://www.cytodyn.com/newsroom/press-releas...rmation-to
IMO It may be interesting to see what the FDA did say about the receptor occupancy listed in the application from 2020.
(11)
(0)
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
Scroll down for more posts ▼
